As the world longs for a return to normal life after more than a year through the pandemic, countries are rushing to deliver vaccines that should slow – and hopefully stop – the spread of the coronavirus.
Success will depend on a whole host of factors, from manufacturing and transporting billions of doses, to ensuring that rich countries do not monopolize the global vaccine supply and, most importantly, injecting doses into arms of people.
The charts and maps below will be updated to show the most recent data on the largest immunization deployment in history, in the United States and around the world.
There are notable differences from state to state in how quickly vaccines are given to people.
The first two vaccines approved for emergency use in the United States, developed by the companies Pfizer / BioNTech and Moderna, are designed to be administered in two doses several weeks apart. The Johnson & Johnson vaccine, which was authorized for use at the end of February, requires only one dose. So, vaccinating everyone in the United States will ultimately mean administering between 100 and 200 doses per 100 people in each state and territory – a total of between 330 million and 660 million doses nationwide. It’s a huge logistical challenge.
The deployment of vaccines in the United States has started more slowly than expected. The Trump administration has set a goal of donating 20 million vaccines by the end of 2020. This goal was not met until the end of January. In early March, President Joe Biden said the United States would have enough vaccines for all adults by the end of May – two months earlier than his administration had previously predicted. Yet there are fears that the vaccination campaign is leaving behind the poorest people and communities of color.
Search or browse this table to find out how your state or territory is performing on these key measures of vaccine deployment.
Vaccine deployment schedule
This graph shows the number of vaccines administered per 100 people for each state starting in early 2021. The top three states and US national numbers are highlighted. Type the name of any other US state or territory in the search bar and select to add it to the chart.
This graph shows the daily number of vaccine doses administered to people across the country since the start of 2021. Due to spikes in data due to delays in reporting, the row showing the 7-day moving average of doses administered gives a clearer idea of whether the deployment is speeding up or slowing down.
Vaccine deployment by country
More countries appear on this map showing vaccine doses given per 100 people because these numbers are more widely reported.
The United States is ahead of most other countries in vaccine deployment. But among the great nations, Israel was the first leader.
Search or browse this table to see how each nation is doing. It reveals that some countries have adopted different strategies: the UK, for example, decided to give as many people as possible an initial dose, thus delaying their second injection.
Vaccine deployment schedule
This graph shows the number of vaccines administered per 100 people for each country from the start of 2021. Type the name of any country in the search bar and select to compare its schedule with the United States and the other three leading countries in vaccine deployment in the world. Only countries that have started their vaccination campaigns will appear.
This graph shows the reported daily number of vaccine doses given to people around the world. Due to spikes due to reporting delays, the row showing the 7-day moving average of doses delivered gives a clearer picture of whether the rollout is speeding up or slowing down.
Status of main vaccines
This table documents the status of major COVID-19 vaccines, showing authorizations for use in the United States and other selected markets, as well as prices for purchase agreement information compiled by UNICEF, the optionally.
The vaccines from Pfizer / BioNTech and Moderna, which clinical trial results indicate are over 90% effective in preventing disease, are based on new technology that delivers an RNA sequence that allows our own cells to produce viral proteins, triggering an immune system. reply.
The downside is that these vaccines are more expensive than those made by splicing the genetic material of the coronavirus into a deactivated version of another virus, like those produced by the Anglo-Swedish company AstraZeneca, based on research from the University. of Oxford, Johnson & Johnson, and the Russian Gamaleya Research Institute.
Other leading vaccines are based on inactivated versions of the coronavirus, a long-standing approach to making vaccines, or protein subunits of the virus.
Jeremy Singer-Vine contributed reporting for this story.